Aptar CSP Technologies Receives $19 Million Government Contract
The $19 million contract will expand production capacity of Aptar’s Activ-Film technology, which is used in COVID-19 testing kits.
Aptar CSP Technologies announced on Oct. 19th, 2021, that it had received a $19 million government contract for its Activ-Film technology, which is used in COVID-19 testing kits. According to a company press release, APTAR will use this money—funded through the American Rescue Act—to expand domestic production capacity of the technology.
Activ-Film is designed to absorb a specific amount of moisture and other compounds at a customized rate. When integrated into diagnostic dipsticks and lateral flow cassettes, it can protect these materials from moisture or other environmental degradants that can impact test integrity and result accuracy.
“The continued need for testing to mitigate the spread of COVID‐19 along with pandemic‐driven supply chain challenges has led to increased demand for our active material science solutions in the diagnostics space,” said Badre Hammond, vice-president of Commercial Operations, Aptar CSP Technologies, in the press release. “Building on current capacity, this funding will enable current and future partners to expand access to reliable diagnostic solutions for infectious diseases.”
Aptar’s active material science platform technology is used in various electrochemical, lateral flow, and molecular diagnostic test kits. It has been used in oral solid dose drugs, transdermal drug delivery, medical devices, and probiotics. It can be engineered to absorb moisture, emit aromas, reduce pathogens, or scavenge odor, oxygen, or volatile organic compounds.
Source: Aptar CSP Technologies
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
